biostudies-literatureNolan AScience Foundation IrelandEuropean UnionSFI Comprehensive Molecular Analytical Platform (CMAP)SFI Precision Oncology Ireland4141https://www.ebi.ac.uk/biostudies/studies/S-EPMC10452836biostudies-literatureUnknown15(16)RAS proteins are key regulators of cell signalling and control different cell functions including cell proliferation, differentiation, and cell death. Point mutations in the genes of this family are common, particularly in <i>KRAS</i>. These mutations were thought to cause the constitutive activation of KRAS, but recent findings showed that some mutants can cycle between active and inactive states. This observation, together with the development of covalent KRASG12C inhibitors, has led to the arrival of KRAS inhibitors in the clinic. However, most patients develop resistance to these targeted therapies, and we lack effective treatments for other KRAS mutants. To accelerate the development of RAS targeting therapies, we need to fully characterise the molecular mechanisms governing KRAS signCancersProteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib.PMC1045283615-CDA-349575492318/RI/570218/SPP/3522Raso CWynne KKriegsheim AVNolan AKolch WMatallanas DfalseProteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib.RAS proteins are key regulators of cell signalling and control different cell functions including cell proliferation, differentiation, and cell death. Point mutations in the genes of this family are common, particularly in <i>KRAS</i>. These mutations were thought to cause the constitutive activation of KRAS, but recent findings showed that some mutants can cycle between active and inactive states. This observation, together with the development of covalent KRASG12C inhibitors, has led to the arrival of KRAS inhibitors in the clinic. However, most patients develop resistance to these targeted therapies, and we lack effective treatments for other KRAS mutants. To accelerate the development of RAS targeting therapies, we need to fully characterise the molecular mechanisms governing KRAS sign2023-01-01T00:00:00Z2023 Aug2026-04-08T14:30:23.782Z2024-10-18T23:15:56.985ZS-EPMC104528363762716910.3390/cancers15164141